Related references
Note: Only part of the references are listed.Perspectives of HER2-targeting in gastric and esophageal cancer
James N. Gerson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
The EMT spectrum and therapeutic opportunities
Dominic C. Voon et al.
MOLECULAR ONCOLOGY (2017)
MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells
Tao Jiang et al.
ONCOLOGY REPORTS (2017)
Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines
Xin Wang et al.
ONCOTARGET (2017)
Targeted therapies for gastric cancer: failures and hopes from clinical trials
Maria Apicella et al.
ONCOTARGET (2017)
Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma
Nabiel Mir et al.
CURRENT CANCER DRUG TARGETS (2017)
Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial mesenchymal transition (EMT)
Qiong Pan et al.
CANCER LETTERS (2017)
An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
Geny Piro et al.
CLINICAL CANCER RESEARCH (2016)
Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer
Chiara Arienti et al.
ONCOTARGET (2016)
Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
Sharon T. Wilks
BREAST (2015)
Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer
Adela Madrid-Paredes et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
Chan-Young Ock et al.
CLINICAL CANCER RESEARCH (2015)
HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases
Rocco Cappellesso et al.
HUMAN PATHOLOGY (2015)
Molecular profiling of tumour budding implicates TGF-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma
D. H. Jensen et al.
JOURNAL OF PATHOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
Carlos Gomez-Martin et al.
CANCER LETTERS (2014)
MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer
Wen-Dong Bai et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review)
Shouji Shimoyama
MOLECULAR AND CLINICAL ONCOLOGY (2014)
Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+Breast Cancer by Expanding the Cancer Stem Cell Population
Hasan Korkaya et al.
MOLECULAR CELL (2012)
LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53
Xinliang Zhou et al.
LIFE SCIENCES (2012)
HER2 Testing in Gastric Cancer
Luca Albarello et al.
ADVANCES IN ANATOMIC PATHOLOGY (2011)
The role of the miR-200 family in epithelial-mesenchymal transition
Perry S. Mongroo et al.
CANCER BIOLOGY & THERAPY (2010)
Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease
Manish A. Shah et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Targeted HER2 Treatment in Advanced Gastric Cancer
Jan Trost Jorgensen
ONCOLOGY (2010)
Targeting HER proteins in cancer therapy and the role of the non-target HER3
A. C. Hsieh et al.
BRITISH JOURNAL OF CANCER (2007)
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
T Fujita et al.
BRITISH JOURNAL OF CANCER (2006)
Share Paper
